pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC


Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

The ‘Ross-Wonders’, Cancer’s New Superheroes


You’ve likely never heard the story of how three young women, who call themselves “ROS1ders” from a rare form of lung cancer they share, may be turning the nation’s 46-year-old war on cancer on its head. The women were diagnosed with a gene mutation called a ROS1 fusion. Read more here

ROS1ders Meet the Rodents


What happens when you tell someone they have a terminal diagnosis and potentially less than a year to live? They cry, get scared, worry about the loved ones they will leave behind, and grieve. And if they are anything like the ROS1ders, they organize and make stuff happen. It has not been easy, and along … Continue reading ROS1ders Meet the Rodents

Announcing a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer


FOR IMMEDIATE RELEASE August 15, 2017 CONTACT: Samantha Cummis Addario Lung Cancer Medical Institute 650-598-2857 Samantha@LungCancerFoundation.org Susan Foreman Champions Oncology, Inc. 410-369-0365 SForeman@ChampionsOncology.com The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer SAN CARLOS, Calif. And Hackensack, … Continue reading Announcing a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer

The Global ROS1 Initiative


The Global ROS1 Initiative is a partnership between several stakeholders interested in ROS1 positive (ROS1+) cancer (also called ROS1 rearranged or ROS1 fusion cancer): The ROS1ders, an international group of patients and carers dealing with ROS1+ cancer spread over 19 countries Patient-focused nonprofits Bonnie J. Addario Lung Cancer Foundation (ALCF) and Addario Lung Cancer Medical … Continue reading The Global ROS1 Initiative

Diagnose ROS1 – und was jetzt?


Wir ROS1-Patientinnen und -Patienten sind selten. So selten, dass wir uns fast nie auf Krankenhausfluren begegnen. Wir treffen einander nicht in der örtlichen Selbsthilfegruppe oder auf Patiententagen. Aber wir wollen uns kennenlernen, denn wir haben ein gemeinsames Schicksal – Lungenkrebs mit einer ROS1-Translokation. Und wir haben brennende Fragen: Wie geht es den anderen Betroffenen, und … Continue reading Diagnose ROS1 – und was jetzt?